Ascendis Pharma A/S Ordinary Share (ASND) Stock Analysis
Sector: Other
AnalystsStrong Buy28 analystsStrengths
- ✓ROE 86.9% — efficient capital deployment
Risks
- ⚠Interest coverage -1.8× — thin debt cushion
What's happening with ASND
Price History
5-Year Weekly Candlestick Chart
About Ascendis Pharma A/S Ordinary Share
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. Show more
The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Employees: 1,189 · Website ↗
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
Valuation
35DP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF36.1xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield2.8%C
Grade C: LowTTM FCF / Market Cap
P/S (TTM)12.08xD
Grade D: ExpensivePrice / TTM Revenue (own statements)
EV/EBITDA42.8xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales11.7xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E19.1xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio22.83xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio0.43A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE86.9%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA44.0%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-31.7%D
Grade D: LowNet Income / Revenue
Operating Margin—
TTM EBIT / TTM Revenue
Gross Margin86.8%A
Grade A: PremiumGross Profit / Revenue
FCF Margin—
FCF / Revenue
True FCF Margin—
TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Implied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue—
TTM stock-based comp / TTM Revenue
Financial Health
12EAltman Z-Score—
Bankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.04xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.72xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-1.8xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity1.93xC
Grade C: MedDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
0EPiotroski F-Score—
Financial strength 0–9. >7 Strong
Beneish M-Score—
Earnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability—
EBIT margin std deviation. Lower = stable
Capex / Revenue—
TTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.55xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$9.94
Cash & short-term investments per share (Finnhub)
Book Value / Share$4.60
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.—
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity—
Shareholders' equity (book value)
Asset / Liability—
Total Assets / Total Liabilities
Market
Market Cap$15.10B
Current Market Capitalization
Beta0.40B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Ratio snapshot Sep 30, 2026
Key Insights: Ascendis Pharma A/S Ordinary Share (ASND)
ASND is up 0.63% today.
- Return on equity of 86.9% is well above the market average.
Insider Transactions
Recent SEC Form 4 filings · 8 records
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Bodenhoff Mads Filed | Bodenhoff Mads | SellOption exercise | -3000 | |
Bodenhoff Mads Filed | Bodenhoff Mads | SellOpen market sale | -3000 | |
Bodenhoff Mads Filed | Bodenhoff Mads | BuyOption exercise | +3.0K | |
HOLTUG LARS Filed | HOLTUG LARS | SellOpen market sale | -236 | |
BIENAIME JEAN JACQUES Filed | BIENAIME JEAN JACQUES | BuyOpen market buy | +900 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
BIENAIME JEAN JACQUES Filed | BIENAIME JEAN JACQUES | BuyOpen market buy | +1.1K | |
SMITH SCOTT THOMAS Filed | SMITH SCOTT THOMAS | BuyOpen market buy | +100 | |
SMITH SCOTT THOMAS Filed | SMITH SCOTT THOMAS | BuyOpen market buy | +250 |
See how ASND ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all ASND moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 23 | Regular | 221.69 | -6.69% | -2.19 |
Frequently Asked Questions about ASND
What is the current Ascendis Pharma A/S Ordinary Share (ASND) stock price?
ASND is trading at $229.50 in the regular session, up 0.63% on the session. PreMarketPrice tracks ASND pre-market, intraday and after-hours prices.
Is ASND stock a buy right now?
PreMarketPrice's quantitative model rates Ascendis Pharma A/S Ordinary Share's financial health at 12/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ASND stock overvalued?
Ascendis Pharma A/S Ordinary Share trades at a trailing P/E of n/a and our valuation score rates it 35/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Ascendis Pharma A/S Ordinary Share report earnings?
No confirmed earnings date is currently scheduled for ASND. The Earnings section lists recent reports and updates as dates are announced.
What sector does Ascendis Pharma A/S Ordinary Share operate in?
Ascendis Pharma A/S Ordinary Share operates in the Other sector. The Related Stocks section lists sector peers for comparison.
What does Ascendis Pharma A/S Ordinary Share do?
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients.
About Ascendis Pharma A/S Ordinary Share (ASND) Stock
Ascendis Pharma A/S Ordinary Share (ASND) is a US-listed stock operating in the Other sector. As of the latest update, Ascendis Pharma A/S Ordinary Share is trading at $229.50, up 0.63% on the day with a market capitalization of $15.1 billion. The financial health score for ASND is 12/100, which indicates poor financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ASND stock.
ASND Stock Analysis & Key Metrics
On PreMarketPrice, you can track Ascendis Pharma A/S Ordinary Share (ASND) across multiple dimensions:
- Pre-market price & movement: Real-time ASND stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ASND with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Ascendis Pharma A/S Ordinary Share across multiple reporting periods.
- Financial health score: A composite score of 12/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ASND.
- Sector peers: Compare ASND against 10 other other stocks on key financial metrics.
Is ASND a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Ascendis Pharma A/S Ordinary Share (ASND) as an investment. The financial health score of 12/100 suggests poor financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Ascendis Pharma A/S Ordinary Share (ASND) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.